Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
DEPT OF DEFENSE has floated a tender for Radiopharmaceuticals (Lutathera and Pluvicto). The project location is USA and the tender is closing on 08 May 2024. The tender notice number is W81K00-24-SS-BAMC-RADIOPHARMACEUTICALS, while the TOT Ref Number is 100535344. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.
Procurement Summary
Country : USA
Summary : Radiopharmaceuticals (Lutathera and Pluvicto)
Deadline : 08 May 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 100535344
Document Ref. No. : W81K00-24-SS-BAMC-RADIOPHARMACEUTICALS
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Purchaser : DEPT OF DEFENSE
Contracting Office Address : JBSA FT SAM HOUSTON, TX 78234-4504
Primary Point of Contact : ROSALBA MARTINEZ
rosalba.martinez1.civ@health.mil
Secondary Point of Contact : Andrea Vigliotti
andrea.j.vigliotti.civ@health.mil
USA
Email :rosalba.martinez1.civ@health.mil
Tender Details
Description
Sources Sought notice is a market research tool being used to determine availability and adequacy of potential business sources.
The Medical Readiness Contracting Office-West is issuing this Sources Sought Notice on behalf of Brooke Army Medical Center (BAMC) JBSA - Fort Sam Houston, Texas. Any responses to this Sources Sought Notice will be used for planning purposes only. Based on the responses to this notice, the requirement may be set-aside for small businesses, procured through full-and-open competition, or result in a sole-source contract. The proposed North American Industry Classification System (NAICS) Code is 325412, Pharmaceutical Preparation Manufacturing, with a corresponding size standard of 1, 300 employees.
BAMC has a requirement for LUTATHERA and PLUVICTO doses. This requirement is for two FDA Approved products. Lutathera, is indicated for the imaging and treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Pluvicto is for the treatment of adult patients with prostrate specific membrane antigen-positive metastatic castration-resistant prostate cancer. The contemplated contract type is an Indefinite-Delivery Indefinite-Quantity contract with firm-fixed-price line items.
Medications will be delivered from 01 October 2024 - 30 September 2029. (Five (5) Ordering Periods)
Salient Characteristics:
Lutetium Lu-177 Dotatate (Lutathera)
Must be FDA approved.
Must be Lu-177 Dotatate.
Must be indicated for treatment of somatostatin receptor-positive gastroenterpancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.
Should be a 4 dose treatment regimen given every 8 weeks.
Lutetium Lu-177 Vipivotide Tetraxetan (Pluvicto)
Must be FDA approved.
Must be Lu-177 Vipivotide Tetraxetan.
Must be indicated for treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant pro...
Active Contract Opportunity Notice ID W81K00-24-SS-BAMC-RADIOPHARMACEUTICALS Related Notice Department/Ind. Agency DEPT OF DEFENSE Sub-tier DEPT OF THE ARMY Major Command MEDCOM Office W40M USA HCA
General Information
Contract Opportunity Type: Sources Sought (Original)
All Dates/Times are: (UTC-05:00) CENTRAL STANDARD TIME, CHICAGO, USA
Original Published Date: Apr 26, 2024 09:15 am CDT
Original Response Date: May 08, 2024 03:00 pm CDT
Inactive Policy: 15 days after response date
Original Inactive Date: May 23, 2024
Initiative: None
Classification
Original Set Aside:
Product Service Code: 6505 - DRUGS AND BIOLOGICALS
NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing
Place of Performance: JBSA Ft Sam Houston, TX 78234 USA
Documents
Want To Bid in This Tender?
Get Local Agent Support in USA and 60 More Countries.
View Tenders By
Sign in with Google